Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.45 |
| ▸ | NQO2 | P16083 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693150 | 0.88 | GPR35 (0.50) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL1166903 | 0.86 | PDE4D (0.45) | PDE4DNQO2PDE4APDE4BPDE4C | |
| SCHEMBL10082469 | 0.85 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CMAPT | |
| SCHEMBL561626 | 0.85 | GPR35 (0.47) | PDE4DMAPTLCKMAPK1MRGPRX4 | |
| SCHEMBL10136815 | 0.85 | NQO2 (0.43) | PDE4DNQO2MAPTLCKMAPK1 | |
| SCHEMBL1166603 | 0.84 | KDM4A (0.43) | PDE4DNQO2PDE4APDE4BPDE4C | |
| SCHEMBL13074496 | 0.84 | PDE4D (0.42) | PDE4DNQO2MAPTLCKMAPK1 | |
| SCHEMBL562408 | 0.84 | GRM2 (0.41) | PDE4DNQO2MAPTLCKMAPK1 | |
| SCHEMBL12809264 | 0.84 | LCK (0.40) | PDE4DNQO2MAPTLCKMAPK1 | |
| SCHEMBL10082467 | 0.84 | PDE4D (0.40) | PDE4DPDE4APDE4BPDE4CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| EP-1673385-A4 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INT (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1673385-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | Boehringer Ingelheim International GmbH (DE) | 2006-06-28 | — | — | EP | disclosed |
| CN-1791599-A | Hepatitis c inhibitor compounds | BOEHRINGER INGELHEIM INT (DE) | 2006-06-21 | — | — | CN | disclosed |
| EP-1654261-A1 | HEPATITIS C INHIBITOR COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| US-20050080005-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-04-14 | — | — | US | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| US-20050020503-A1 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103996-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | PDE4D 1418/4885NQO2 909/4885PDE4A 872/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | PDE4D 1418/4885NQO2 909/4885PDE4A 872/4885 |
| US-20050020503-A1 | Hepatitis C inhibitor compounds | HAVCR2, CTRL, CTRC | PDE4D 4640/4885NQO2 950/4885PDE4A 4031/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | PDE4D 1418/4885NQO2 909/4885PDE4A 872/4885 |
| US-20050080005-A1 | Macrocyclic peptides active against the hepatitis C virus | CTRL, RPP30, RNASE1 | PDE4D 3339/4885NQO2 3233/4885PDE4A 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.